De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review

De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review

Saved in:

Bibliographic Details
Main Authors:	Hanxu Guo, Chengqi Jin, Li Ding, Jun Xie, Jing Xu, Ruiliang Wang, Hong Wang, Changcheng Guo, Jiansheng Zhang, Bo Peng, Xudong Yao, Jing Yuan, Bin Yang, Sihan Zhou
Format:	Article
Language:	English
Published:	Wolters Kluwer 2025-01-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003311
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study
by: Fumihiko Urabe, et al.
Published: (2025-03-01)

The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer
by: Tessa van Elst, et al.
Published: (2025-04-01)

Therapy-Related Leukemia following Docetaxel Chemotherapy for Metastatic Hormone-Sensitive Prostate Cancer: A Case Report
by: Chen Zhu, et al.
Published: (2024-12-01)

Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer
by: Hejar Atalan, et al.
Published: (2025-06-01)

A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK
by: Louisa Fleure, et al.
Published: (2024-11-01)

Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta
by: Emilio Jesús Alegre del Rey, et al.
Published: (2017-07-01)

Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better
by: Omer Dizdar, et al.
Published: (2019-08-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-05-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-05-01)

Disseminated Intravascular Coagulation as an Initial Manifestation of Metastatic Prostate Cancer Emergently Treated with Docetaxel-Based Chemotherapy
by: Kavita Agrawal, et al.
Published: (2019-01-01)

Real-world effectiveness of novel hormonal agents and docetaxel in patients with prostate cancer: A head-to-head comparison
by: Yuanshi Jiao, et al.
Published: (2025-04-01)

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach
by: Almudena Zapatero, et al.
Published: (2025-07-01)

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
by: Tobias Engel Ayer Botrel, et al.
Published: (2016-01-01)

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer
by: Zhiyu Zhang, et al.
Published: (2025-08-01)

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis
by: Azka Syed, et al.
Published: (2025-07-01)

Docetaxel-induced syndrome of inappropriate antidiuretic hormone secretion
by: Tamojit Chaudhuri, et al.
Published: (2013-01-01)

An example of drug repurposing: ebastine in combination with docetaxel as a treatment for metastatic castration-resistant prostate cancer–the EXUROC prostate study, a clinical trial protocol
by: Katrine Ørum, et al.
Published: (2025-07-01)

The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer
by: Eun-mi Yu, et al.
Published: (2024-09-01)

Enhancing in Vitro anti-metastatic efficacy and deep penetration into tumor spheroid of docetaxel-loaded liposomes via size optimization for prostate cancer treatment
by: Saksorn Klibaim, et al.
Published: (2025-03-01)

Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer
by: Jochen Greiner, et al.
Published: (2010-01-01)

Perioperative outcomes of esophagectomy after doublet versus docetaxel‐based triplet neoadjuvant chemotherapy in older patients: A nationwide inpatient database study in Japan
by: Yuki Hirano, et al.
Published: (2025-07-01)

A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer
by: Aryan Dalal, et al.
Published: (2024-01-01)

Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer
by: Yasutaka Yamada, et al.
Published: (2025-03-01)

Disease burden and treatment choice for metastatic hormone-sensitive prostate cancer in Colombia
by: Ray Manneh-Kopp, et al.
Published: (2025-01-01)

Towards personalized prostate cancer treatment with docetaxel in indonesia: a pharmacogenomics perspective
by: Jekmal Malau, et al.
Published: (2025-04-01)

Silk protein discoidal microparticles for site-specific delivery of docetaxel in metastatic lung cancer
by: Hyeyoun Cho, et al.
Published: (2025-10-01)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01)

Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.
Published: (2015-01-01)

Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons
by: Hui-Ai Zeng, et al.
Published: (2025-02-01)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
by: Masayoshi Zaitsu, et al.
Published: (2012-01-01)

Editorial: Metastatic hormone-sensitive prostate cancer: new therapeutic strategies to improve patient outcome
by: Ludmilla T. D. Chinen, et al.
Published: (2025-04-01)

Magnetic Resonance or Computed Tomography and Bone Scan for Staging Metastatic Hormone–Sensitive Prostate Cancer
by: Mona Ali Hassan, et al.
Published: (2025-05-01)

Multicenter Real-World Study: 432 Patients with Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
by: Juan A. Encarnación Navarro, et al.
Published: (2025-02-01)

Prostate radiotherapy in patients with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis of randomised controlled trials
by: Navid Roessler, et al.
Published: (2025-09-01)

Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer
by: Mike Wenzel, et al.
Published: (2025-07-01)

Interglobular Diffusion of an Energy Donor in Triplet-Triplet Energy Transfer in Proteins
by: Andrey G. Melnikov, et al.
Published: (2013-01-01)

Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients
by: Shuai Yuan, et al.
Published: (2024-12-01)

Survival Benefit of Radical Prostatectomy in Newly Diagnosed Metastatic Prostate Cancer Varies by PSA Level and Site of Metastasis
by: Xin Zhang, et al.
Published: (2025-12-01)

The Silent Burden of De Novo Metastatic Prostate Cancer in the Middle East: A Call for Region-Specific Screening Guidelines
by: Noura Abbas, et al.
Published: (2025-02-01)

Triplet–Triplet Annihilation-Based Photon Upconversion with a Macrocyclic Parallel Dimer
by: Catherine H. Mulyadi, et al.
Published: (2024-09-01)